J. Sackner-Bernstein

发表

Resynchronization and Defibrillation for Heart Failure: A Practical Approach

Paul J. Wang, D. Hayes, S. Asirvatham, 2004 .

HFSA 2006 comprehensive heart failure practice guideline

Prakash Deedwania, John Boehmer, J. H. Patterson, 2006 .

Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline

J. H. Patterson, Randall C. Starling, Prakash C. Deedwania, 2022 .

Nesiritide for acute decompensated heart failure: Does the benefit justify the risk?

K. Aaronson, J. Sackner-Bernstein, 2007, Current cardiology reports.

Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy

J. Sackner-Bernstein, 2005, Clinical cardiology.

Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure

J. Sackner-Bernstein, 2005, Current cardiology reports.

Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure.

J. Sackner-Bernstein, 2004, The American journal of cardiology.

Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline.

C. Cannon, M. Gheorghiade, G. Fonarow, 2003, Critical pathways in cardiology.

Activation and release of degradative proteinases within the myocardium are the trigger for ventricular remodeling in chronic heart failure.

J. Sackner-Bernstein, 2002, Medical hypotheses.

Hypertensive End-Organ Damage and Premature Mortality Are p38 Mitogen-Activated Protein Kinase–Dependent in a Rat Model of Cardiac Hypertrophy and Dysfunction

John C. Lee, J. Adams, C. Angermann, 2001, Circulation.

Use of carvedilol in chronic heart failure: challenges in therapeutic management.

J. Sackner-Bernstein, 1998, Progress in cardiovascular diseases.

Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.

H. Krum, M. Miller, M. Packer, 1996, American heart journal.

Rationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade

D. Mancini, J. Sackner-Bernstein, 1995 .

New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.

J. Sackner-Bernstein, 2003, Reviews in cardiovascular medicine.

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

S. Gottlieb, R. Cody, T. LeJemtel, 1996, Circulation.

Risk of Death With Nesiritide—Reply

K. Aaronson, J. Sackner-Bernstein, 2005 .

Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction.

C. Cannon, M. Gheorghiade, G. Fonarow, 2003, Reviews in cardiovascular medicine.

Mechanisms Underlying Improvements in Ejection Fraction With Carvedilol in Heart Failure

D. Burkhoff, D. King, M. Maurer, 2009, Circulation. Heart failure.

Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure.

J. Bigger, H. Krum, R. Steinman, 1997, The American journal of cardiology.

Rationale for treatment of patients with chronic heart failure with adrenergic blockade.

R. Pizov, D. Mancini, J. Sackner-Bernstein, 1996, JAMA.

Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure

K. Aaronson, J. Sackner-Bernstein, H. Skopicki, 2005, Circulation.

Nesiritide--not verified.

K. Aaronson, J. Sackner-Bernstein, 2005, The New England journal of medicine.

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

J. A. Bowers, J. Cohn, S. Krueger, 1996, Circulation.

Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.

K. Aaronson, J. Sackner-Bernstein, M. Kowalski, 2005, JAMA.

Risk of death associated with nesiritide in patients with acutely decompensated heart failure.

K. Aaronson, J. Sackner-Bernstein, 2006, JAMA.

Is there risk associated with the use of nesiritide for acute heart failure

J. Sackner-Bernstein, M. Kowalski, Marshal T. Fox, 2003 .

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease

C. Angermann, R. Coatney, R. Willette, 2004, Journal of Hypertension.

Evidence Against Heart Rate Reduction as the Primary Mechanism of Action of Carvedilol in Chronic Heart Failure

J. Sackner-Bernstein, M. Lukas, B. Wu, 1998 .

Cardiogenic pulmonary edema

J. Sackner-Bernstein, H. Skopicki, 2006 .

Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension

J. Sackner-Bernstein, D. Hering, Michael A. Weber, 2022, Hypertension.

Increasing organ transplantation--fairly.

S. Godin, J. Sackner-Bernstein, 2004, Transplantation.

Estimates of Intracellular Dopamine in Parkinson’s Disease: A Systematic Review and Meta-Analysis

J. Sackner-Bernstein, 2021, Journal of Parkinson's disease.

What Is the Greatest Regulatory Challenge in the Translation of Biomaterials to the Clinic?

Chris Mason, Glenn D Prestwich, Christopher K Breuer, 2012, Science Translational Medicine.

What is the role of biventricular pacing the transplant candidate?

J. Sackner-Bernstein, D. M. Farmer, 2004, Coronary artery disease.

The myocardial matrix and the development and progression of ventricular remodeling

J. Sackner-Bernstein, 2000, Current cardiology reports.

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

H. Krum, M. Packer, M. Kukin, 1995, Circulation.

Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.

S. Pressler, J. Udelson, J. Sackner-Bernstein, 2006, The American journal of cardiology.

Racing away from bias.

J. Sackner-Bernstein, H. Skopicki, 2004, Journal of the American College of Cardiology.

S. Gottlieb, R. Cody, T. LeJemtel, 1996, Circulation.

Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials

K. Aaronson, J. Sackner-Bernstein, M. Kowalski, 2005 .

Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis

S. Kaul, J. Sackner-Bernstein, David Kanter, 2015, PloS one.

Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.

J. Massaro, S. Pressler, J. Udelson, 2009, Journal of cardiac failure.

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

C. O'connor, M. Gheorghiade, M. Metra, 2010, American heart journal.

Robotically assisted left ventricular epicardial lead implantation for biventricular pacing.

Jonathan Sackner-Bernstein, J. Sackner-Bernstein, R. Shaw, 2003, Journal of the American College of Cardiology.

FDA Approval of Eteplirsen for Muscular Dystrophy.

J. Sackner-Bernstein, 2017, JAMA.

Design of Hack-Resistant Diabetes Devices and Disclosure of Their Cyber Safety

Jonathan Sackner-Bernstein, J. Sackner-Bernstein, 2017, Journal of diabetes science and technology.